November 25, 2020

The Niche

Knoepfler lab stem cell blog

Johnson & Johnson

5 min read

The FDA in the past year or so has issued draft guidances on regulation of stem cells that would, if finalized, make it crystal clear that what many American stem cell clinics are selling are unapproved drugs. That would be a good thing for patients who are often being put at risk by many of the clinics. This is the reality no matter what some of the patient advocates who promote the clinics might say. Such finalized FDA regs that unambiguously state that, for …Read More

2 min read

Big Pharma Giant Johnson & Johnson (J & J; $JNJ) announced today a $12.5 million investment in stem cells & regenerative medicine via the small biotech Capricor ($CAPR) and the potential for the bet to go into the hundreds of millions for the heart disease program. It was only 8 days ago that I made my stem cell predictions for 2014 and #3 on the list was “Big announcement  from “Big Pharma” on stem cells or regenerative medicine.” Chalk that up for the crystal ball of …Read More